Physician profile
John M Hernandez
NPI 1073683546
$9,169.98
in general payments reported to CMS, 2019-2025
44 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $1,728 · 2021: $1,994 · 2022: $1,259 · 2023: $1,537 · 2024: $849 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.92 |
| Education | $137.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $781.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $664.48 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $659.96 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $625.45 | 2019-2022 | |
| Pfizer INC. | $606.18 | 2019-2025 | |
| Novo Nordisk INC | $541.16 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.50 | 2020-2024 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $469.15 | 2019-2024 | |
| Glaxosmithkline, LLC. | $457.96 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $437.02 | 2021-2025 | |
| Amgen INC. | $426.72 | 2019-2025 | Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.15 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $315.97 | 2019-2021 | |
| Radius Health, INC. | $243.42 | 2019-2023 | Tymlos |
| Mannkind Corporation | $211.37 | 2021-2025 | Afrezza |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $190.02 | 2019-2022 | |
| Zynex Medical, INC. | $179.04 | 2023 | Nexwave |
| Novartis Pharmaceuticals Corporation | $150.37 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $150.20 | 2019-2022 | |
| Almatica Pharma LLC | $141.77 | 2021-2023 | Loreev Xr, Gralise |
| Merck Sharp & Dohme LLC | $133.75 | 2019-2021 | |
| Biotronik INC. | $130.59 | 2019 | |
| Amarin Pharma, INC. | $112.77 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.59 | 2021 | |
| Corcept Therapeutics | $75.11 | 2025 | Korlym |
| Allergan, INC. | $74.23 | 2019-2020 | |
| Boston Scientific Corporation | $70.76 | 2019-2022 | |
| Dexcom, INC. | $56.74 | 2022 | |
| Exact Sciences Corporation | $51.13 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $43.75 | 2024-2025 | Zoryve |
| Medtronic, INC. | $34.89 | 2022-2023 | Minimed 770g |
| Inari Medical, INC. | $34.79 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cequr Corporation | $28.17 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.70 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $22.99 | 2024 | Rexulti |
| Genentech USA, INC. | $22.65 | 2020 | |
| Corium, LLC | $20.39 | 2022 | |
| Horizon Therapeutics Plc | $19.20 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.13 | 2020 | |
| Eisai INC. | $12.55 | 2021 | |
| Kvk-Tech, INC. | $4.31 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.